No Data
Jinkai Biological Science (301509.SZ): Core products are applied in the treatment fields of multiple diseases including tumors, cardiovascular and cerebrovascular diseases, diabetes, and kidney diseases.
On January 13, Gelonghui reported that Jinkaishengke (301509.SZ) stated on the investor interaction platform that the company is a small molecule CDMO service provider aimed at Global life science clients, offering customized research, development, and synthesis production services for small molecule drug intermediates and small quantities of Active Pharmaceutical Ingredient for new drug development projects of Global original drug manufacturers. The company's core products are applied in multiple disease treatment areas, including oncology, cardiovascular, diabetes, and kidney diseases.
Kingchem (Liaoning) Life Science Co., Ltd. (SZSE:301509) Investors Are Less Pessimistic Than Expected
GenScript Biotech Corporation (301509.SZ): Qilu Investment, Blue Zone Fund, and Qingsong Investment plan to collectively reduce their shareholding by no more than 9%.
Glory Union reported on November 26 that Jinkai Biological (301509.SZ) announced that Qilu Investment plans to reduce its shareholding through centralized bidding and block trading by no more than 3,612,000 shares (accounting for 3% of the company's total equity). Blue Area Fund plans to reduce its shareholding through centralized bidding and block trading by no more than 3,612,000 shares (accounting for 3% of the company's total equity). Qingsong Investment plans to reduce its shareholding through centralized bidding and block trading by no more than 3,612,000 shares (accounting for 3% of the company's total equity).
Jinkai Shengke: Report for the third quarter of 2024
Genecast Biotechnology (301509.SZ): The company's products do not involve starch or other fillers and excipients.
Golden Triumph October 23rd | Jin Kaiseng Science (301509.SZ) stated on the investor interaction platform that the company provides small molecule CDMO services, and the company's products do not involve starch and other fillers and excipients.
Jinkaisen Life Sciences (301509.SZ): The net income in the third quarter was 7.1988 million yuan, a year-on-year decrease of 79.02%.
GeLongHui October 23rd | Jinkaiseng Science and Technology (301509.SZ) announced its third quarter report for 2024, with revenue of 0.125 billion yuan for the reporting period, a decrease of 18.72% year-on-year; net income attributable to shareholders of the listed company was 7.1988 million yuan, a decrease of 79.02% year-on-year; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 0.4557 million yuan, a decrease of 98.66% year-on-year; basic earnings per share were 0.06 yuan.
